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ABSTRACT OF THESIS

APOE GENOTYPE AND SEX
MODULATE KETOGENIC DIET ENHANCEMENTS
TO METABOLISM AND GUT MICROBIOME IN YOUNG MICE
The apolipoprotein ε (APOE) allele in humans has been associated with risk for
development of Alzheimer’s disease (AD). There are predominately three variations of the
allele – ε2 (E2), ε3 (E3), and ε4 (E4) – with E4 contributing the greatest risk of AD
development. Recent research has unveiled evidence of neurometabolic and neurovascular
deficits in E4 carriers present decades before the onset of dementia; it is believed these
chronic defects play a major role in the development of AD, thus making them a potential
target for preventative intervention. The purpose of this study was to examine the effect of
a ketogenic diet (KD) on cerebral metabolites, gut microbiome, and cerebral perfusion in
young transgenic mice carrying the E4 allele. Here we show that within 16 weeks, the
control E4 female mice had the worst outcomes, while the KD significantly rescued E4
female health markers compared to the other groups.
KEYWORDS: Alzheimer’s Disease, Apolipoprotein ε, Ketogenic Diet, APOE Targetreplacement (APOE-TR), gut microbiome, neurodegenerative disease.
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1. INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized
by a decline in cognitive function and the development of dementia. AD is currently the
most common global cause of dementia and prevalence continues to rise with few
available treatments of only limited efficacy (Lane et al., 2018). The apolipoprotein ε4
(APOE4) allele is the single greatest genetic risk factor for sporadic (late-onset) AD: E4
homozygotes have an eight- to twelve-fold increased risk compared E3 homozygotes
(2021). In addition to genetics, a marked sex difference in response to the APOE4 allele
has also been demonstrated in humans: female E4 carriers have a greater risk of
developing AD, show accelerated progression of the disease, and have more severe
cognitive and memory decline than males with the same APOE polymorphism (Altmann
et al., 2014).
Although AD is a neurodegenerative disorder, accumulating evidence suggests that
systemic metabolic dysfunction and inflammation contribute greatly to the risk of
developing AD. Recent research highlights the presence of neurometabolic and
neurovascular deficits decades before clinical presentation in APOE4 carriers. In line
with this, patients with AD show metabolic dysfunction, such as impaired glucose
utilization in the brain (Calsolaro and Edison, 2016). Impaired glucose metabolism can
subsequently contribute to the development of insulin resistance, Type II diabetes
mellitus (T2DM), hyperlipidemia, obesity, or other metabolic disorders that may further
increase the risk of AD (Pistollato et al., 2016). Short-Chain Fatty Acid (SCFA)
deficiency has been associated with T2DM; metabolic dysfunction including
inflammation, insulin resistance and endoplasmic reticulum stress, are known to underlie
T2DM in peripheral tissues (Hotamisligil, 2006). A similar condition has also been
described in the brains of AD patients; thus, some groups have even described AD as
Type 3 diabetes mellitus (T3DM) (Nguyen et al., 2020). Interventions that could alleviate
inflammation and restore metabolic function systemically may ultimately reduce the risk
of T2DM and AD. Another risk factor related to metabolic syndrome is dysbiosis of the
gut microbiota, which is also considered to contribute to AD development through
unknown mechanisms (Altmann et al., 2014; Pistollato et al., 2016).
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Cerebral blood flow (CBF) reductions also occur in AD, and the E4 allele contributes
to CBF reductions in pre-symptomatic E4-carriers prior to any decline in cognitive
function (Matsuda, 2001). This hypoperfusion is thought to be yet another contributing
factor to AD pathogenesis due to an inability for the body to appropriately supply
necessary metabolites to the brain in concert with diminished clearance of A-Beta
plaques accumulating in the brain’s vasculature. In addition to changes in cerebral
perfusion, diffusion tensor MRI (DT-MRI or DTI) measurements in AD patients have
shown a decline in white matter integrity in AD brains (Bozzali et al., 2002). Whether or
not there is evidence of similar changes in pre-clinical AD E4-carriers is currently up for
debate. This decline in white matter integrity is thought to be a byproduct of cerebral
hypometabolism, leading to a compensatory response that scavenges the brain for energy
sources and ultimately strips away myelin sheaths to repurpose as fatty acid energy
metabolites.
In response to the growing evidence of gut microbiota and metabolic deficiencies,
dietary interventions are now being explored as a possible treatment for AD. Recent
studies demonstrating that treatment of systemic inflammation and metabolic dysfunction
can reverse cognitive decline and prevent development of AD (Bredesen et al., 2016).
These studies encourage us to anticipate that early KD intervention can reduce the risk of
developing AD.
The ketogenic diet (KD) is a low-carbohydrate and fat-rich diet that has been used in
treating epilepsy (Baranano and Hartman, 2008), Parkinson’s disease (Wlodarek, 2019),
amyotrophic lateral sclerosis (Zhoa et al., 2006), and autism (Napoli et al., 2014).
Attention has turned to KD as a possible clinical intervention because it induces a
metabolic state of ketosis in which the brain and body uses ketone bodies (KBs) as an
adaptive fuel source to supplement the insufficient carbohydrate energy supply (Cunnane
et al., 2016; Rusek et al., 2019). Furthermore, KBs are considered a more efficient energy
source than glucose, as they bypass glycolysis and directly enter the Krebs Cycle. KBs
have also been associated with neuroprotective properties (Maalouf et al., 2009). These
properties of KBs have the potential to alleviate the effects of the impaired glucose
metabolism associated with AD. Moreover, the diet may help to reduce the accumulation
of Aβ plaques and reverse Aβ toxicity (Broom et al., 2019). Research has also shown that
2

KD modulates both gut microbiome and SCFA levels in AD patients (Ma et al., 2018;
Nagpal et al., 2019). Research in wildtype mice demonstrates that KD can improve CBF
as well (Ma et al., 2018).
Despite the growing interest in KD, there is a lack of research into the interactions
between sex, genotype, and diet. Therefore, the purpose of this study was to investigate
KD as a nutritional intervention for AD prevention in young APOE3 and APOE4 male
and female transgenic mouse models of AD. We fed (9 week) old mice either a ketogenic
or control diet for (16) weeks. In this study, we investigated the effects of KD on body
weight, blood ketone bodies and glucose levels, brain metabolites, short chain fatty acid
levels in cecum and plasma, and gut microbiome diversity and composition.
2. MATERIALS AND METHODS

Figure 1. Study design. Special diet regimens were introduced at 12 weeks (3
months) of age. The study mice were fed special diet for 16 weeks (4 months).
Pre-study fecal samples were collected before special diets were given. Poststudy fecal samples were collected 16 weeks after diet start. Behavioral
assessments and MRI scans were done after 16 weeks of feeding, then the study
mice were sacrificed for blood and tissue collection.
2.1.

Experimental design.
C57BL/6 transgenic human APOE3 and APOE4 male and female mice (6-9 weeks

of age) were obtained from Taconic for use in this study (Model numbers 1548 and 1549,
respectively). We determined the sample size with the power that could perform the
comparison at a 0.05 level of significance, with a 90% chance of detecting a true
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difference of all the measurements between the two groups; n = 6-12 per group were used
in the study – Table 1 shows a detailed breakdown for the n of each study group.
Table 1. Detailed breakdown of the final n for each of the 8 study groups.
APOE Genotype

Male Control

Male KD

Female Control

Female KD

APOE3

n = 11

n=9

n = 12

n = 12

APOE4

n=9

n=9

n = 12

n=6

After arriving at our facilities, each mouse was given its own cage housed in a
specific pathogen-free facility to avoid microbiome transfer. Both the control diet
regimen (type 1515) and ketogenic diet regimen (type F3666) were obtained from BioServ (Table 2). Fecal samples were obtained at two timepoints (baseline and post-study),
and all mice were fed ad libitum for 16 weeks, with the diet beginning at 12 weeks of age
(Figure 1). Body weight was measured every two weeks. The amount of remaining diet
was weighed every two weeks to determine the food intake of the mice. All experimental
procedures were performed according to NIH guidelines and approved by the
Institutional Animal Care and Use Committee (IACUC) at the University of Kentucky
(UK).
Table 2. Comparison of composition of caloric content between the special
Control diet and Ketogenic diet (KD).

Control Diet Caloric Profile
kcal/g
percent

Ketogenic Diet Caloric Profile
kcal/g
percent

Carbohydrate
Fat
Protein

2.61
0.46
0.72

69%
12%
19%

0.13
6.76
0.34

2%
93%
5%

Total

3.79

100%

7.24

100%

2.2.

Fecal Sample Collection.
Fecal samples were collected by putting each mouse in a clean autoclaved cage and

waiting for it to defecate normally. Samples were collected during a 2-hour window from
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8 a.m. to 10 a.m. and frozen at −80 °C until further use. Samples were used to obtain
genomic DNA. QIAGEN DNeasy PowerSoil Kit was used per manufacturers’ guidelines.
2.3.

Gut Microbiome Analysis.
Shotgun metagenomic sequencing was done by CosmosID. Briefly, DNA libraries

were assembled using the CosmosID proprietary library prep kit and pooled by adding an
equimolar ratio of each sample on a high sensitivity chip to estimate size. Libraries were
then sequenced using an Illumina NextSeq/Hiseq platform. Unassembled reads were
directly analyzed by the CosmosID bioinformatics platform (CosmosID Inc., Rockville,
MD), which allows for multi-kingdom microbiome analysis, profiling of antibiotic
resistance and virulence genes, and quantification of relative abundance. CosmosID uses
a high-performance k-mer based algorithm that disambiguates hundreds of millions of
short reads of a sample into the microorganisms that the sequences represent. Matrix
tables of detected taxa were generated, and heat maps were produced. These allow for
visualization of diversity and abundance of each microbial taxa. LEfSe differential
abundance analyses were performed between pairs of cohorts to determine taxa that are
significantly enriched in each cohort.
2.4.

Diversity and Dissimilarity Analysis.
Alpha diversity (within sample, Shannon index) and beta diversity (dissimilarities

between samples, Bray-Curtis index) were performed in order to compare the microbial
community as a whole between different sample groups (i.e. diet, injury). Alpha and beta
diversity analyses were performed by CosmosID (Rockville, MD). Visualizations of
alpha diversity were created using GraphPad Prism 9.0. Visualizations of beta diversity
were created by CosmosID (Rockville, MD), with corresponding PERMANOVA tests,
respectively.
2.5.

Metabolomic Profiling.
All mice were euthanized following MRI scanning with subsequent collection of the

right and left hemispheres of the brain. The tissues were separated into individual tubes
and stored at -80ºC. The right hemisphere of each mouse brain was shipped on dry ice to
Metabolon Inc. (Durham, NC, USA) for subsequent targeted and nontargeted
5

metabolomics analysis. The nontargeted metabolomics protocol has been described
previously in (Hoffman et al., 2019). The targeted metabolomics protocol has been
described in (Evans et al., 2009). See Appendix A for the full protocol from Metabolon
Inc.
2.6.

Short Chain Fatty Acid Analysis of Plasma and Cecal Contents.
Eight SCFAs from cecum and plasma were analyzed with LC-MS/MS by Metabolon

Inc. (Morrisville, NC): acetic acid (C2), propionic acid (C3), isobutyric acid (C4), 2methylbutyric acid (C5), isovaleric acid (C5), valeric acid (C5), and caproic acid (C6).
Both sets of samples were stable labeled with internal standards and homogenized in an
organic solvent. The samples were then centrifuged followed by an aliquot of the
supernatant used to derivatize to form SCFA hydrazides. This reaction mixture was
subsequently diluted, and an aliquot was injected into an Agilent 1290/AB Sciex QTrap
5500 LCMS/MS system.
2.7.

Blood Glucose and Ketone Bodies Measurements.
Blood samples were collected during sacrifice in 500 μl EDTA blood collection tubes

(Vacutainer K2 EDTA) to avoid blood coagulation. A total of 1–2 μl of blood sample
were used to measure blood glucose level using a blood glucose meter and a test strip
(Clarity Plus, Boca Raton, FL, USA). Another 10 μl of blood sample was used for ketone
bodies level measurement using a STAT-Site M (β-Hydroxybutyrate) meter and a test
strip (Standbio Ketosite STAT-Site M-β HB, Boerne, TX, USA).
2.8.

Cerebral Blood Flow (CBF) and Diffusion Tensor MRI (DT-MRI or DTI)

scans.
We used the 7T Clinscan MR scanner (Siemens, Germany) at the Magnetic
Resonance Imaging & Spectroscopy Center of UK. Mice were anesthetized with 4.0%
isoflurane for induction and then maintained in a 1.2% isoflurane and air mixture using a
facemask. Heart rate (90–130 bpm.), respiration rate (70-90 breaths per minute), and
rectal temperature (37 ± 0.5°C) were monitored. A water bath with circulating water at
45–50°C was used to maintain the body temperature. Quantitative CBF (with units of
mL/g per minute) was measured using MRI-based pseudo-continuous arterial spin
6

labeling (pCASL) techniques (Muir et al., 2008). Paired images were acquired in an
interleaved fashion with FOV =18 x 13.5 mm2, matrix = 64 x 48, slice thickness = 1 mm,
6 slices, labeling duration = 200ms, TR = 4,000 ms, TE = 20 ms, and 120 repetitions.
pCASL image analysis was employed with in-house written codes in MATLAB
(MathWorks, Natick, MA) to obtain quantitative CBF (Lin et al., 2015). CBF maps were
visualized and quantitated using Mango image viewer (UT San Antonio, TX). Diffusion
tensor imaging (DTI) is used to characterize microstructural changes in the brain
(Alexander et al., 2007). The images are acquired using four-segment, spin-echo, echoplanar sequence with the following parameters: field of view = 22 x 14.3 mm, 160 × 160
matrix, slice thickness = 1 mm, slice numbers = 4, TR = 1400 ms, TE = 42 ms, 90 degree
flip angle, b value = 0 and 800 s/mm2, diffusion direction = 106, diffusion gradient
amplitude (G) = 10 and 190 mT/m, gradient duration (Δ) = 18 ms, and averages = 1 (Guo
et al., 2015). Fractional Anisotropy (FA) values are analyzed using Mango image viewer
for regions of interest.
2.9.

Statistical analysis.
All statistical analyses were completed using GraphPad Prism (GraphPad, San Diego,

CA, USA). 2-way ANOVA tests were performed for determination of differences
between diet and genotype groups followed by Tukey’s multiple comparisons test. 3-way
ANOVA tests were performed for determination of differences between sexes followed
by Tukey’s multiple comparisons test. Levels of statistical significance were reached
when p < 0.05. Data are represented as mean ± S.E.M. For both the metabolite and
microbiome analysis, given the multiple comparisons inherent in analysis of metabolites,
between-group relative differences are assessed using both p-value and false discovery
rate analysis (q-value).

7

3. RESULTS
3.1.

Diet and APOE Genotype Effects

3.1.1. Mice fed the ketogenic diet (KD) maintained a lower body weight despite
increased caloric intake throughout the study.
As mentioned in the Introduction, AD risk is subject to both genetic and non-genetic
factors. Weight and dietary habits is one such risk factor that can contribute to AD.
Similar to previous studies in APOE-TR mice(Lane-Donovan and Herz, 2016), we found
significant diet effects on body weight for both APOE genotypes (Table 3). Post-hoc
analysis showed significant weight loss in KD groups relative to respective Control
groups (for APOE3 and APOE4: p = 0.0079).
We observed significant diet effects on caloric consumption for comparisons within
the E3 and E4 groups (data not shown). Post-hoc analysis revealed significantly increased
caloric consumption for E3-KD over E3-Ctrl during Week 5 (p = 0.0128), Week 9 (p =
0.0016), Week 11 (p < 0.0001), Week 13 (p = 0.0016), and Week 15 (p = 0.0244).
Additionally, post-hoc analysis showed significantly increased caloric consumption for
E4-KD over E4-Ctrl in Week 5 (p = 0.0006), Week 11 (p = 0.0006), and Week 15 (p =
0.0011).
We also noted significant APOE genotype effects on caloric consumption between
the Control and KD groups. Post-hoc analysis showed significantly increased caloric
consumption for E3-KD over E4-KD during Week 7 (p = 0.0083), Week 9 (p = 0.0043),
and Week 13 (p = 0.0464). We found no significant differences in caloric consumption
for comparisons between E3- and E4-Ctrl groups.
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Table 3. Ketogenic Diet (KD) intervention reduces weight gain in APOE3 and
APOE4 mice. A two-way ANOVA showed significant diet effects (F (1,76) =
10.89; p = 0.0015), but no significant genotype effects. Post-hoc analysis
showed significant weight gain in Control Diet groups compared to respective
KD groups (for APOE3 and APOE4: p = 0.0079).
APOE Genotype
Control Diet (g)
Ketogenic Diet (g)

APOE3
35.39 ± 4.32
32.88 ± 5.36

APOE4
36.56 ± 5.63
31.23 ± 4.73

3.1.2. Ketogenic diet disparately modulated blood ketone bodies (KBs) and glucose
levels.
It has been established that ketone body metabolism contributes neuroprotective
benefits, improvements in mitochondrial efficiency, enhanced protection against reactive
oxygen species (ROS), along with many other metabolic advantages. Consistent with
previous KD studies in WT mice(Kennedy et al., 2007; Ma et al., 2018), we found
significant diet effects on blood KBs for the E3 and E4 comparisons (F (1,63) = 40.49, p
< 0.0001; Fig. 2A). Post-hoc analysis showed significantly elevated levels of blood KBs
in E3-KD over E3-Ctrl (p < 0.0001) and E4-KD over E4-Ctrl mice (p = 0.0015). There
were no significant APOE genotype effects on blood KB (F (1,63) = 0.3061, p = 0.5820).
Diet effects were also present for blood glucose levels (F (1,49) = 5.35, p = 0.0250; Fig.
2B) with a tendency for lower glucose levels following KD. However, post-hoc analysis
did not show statistical significance between groups for either E3 (p = 0.1004) or E4 mice
(p = 0.7882). We did not find APOE genotype effects on blood glucose, either (F (1,49) =
3.23, p = 0.0787).
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Figure 2. KD effects on blood glucose and ketone body levels. (A) Both APOE3KD and APOE4-KD mice had significantly higher blood KB levels compared
to their control counterparts. (B) KD mice trended towards lower blood glucose
levels, but differences did not reach statistical significance in either APOE3 or
APOE4 group. *p < 0.05; **p < 0.01; **** p < 0.0001.
3.1.3. The KD induced recovery in E4 metabolic profile.
To determine the effects of genotype on general metabolic health, the right
hemisphere of each mouse cortex was sent for metabolomic profiling. Genotype contrasts
within control diet groups revealed E4-Ctrl had significantly reduced cortical
concentrations of many amino acids and their neurotransmitter derivatives (aspartate,
asparagine, glutamate, glutamine, and GABA), as well as most TCA cycle intermediates
(citrate, aconitate, isocitrate, succinylcarnitine, succinate, fumarate, and malate)
compared to E3-Ctrl (Table 4A). Additionally, E4-Ctrl had significantly higher cortical
concentrations of oxidized glutathione, potentially highlighting a dysregulation in
antioxidant mechanisms for E4 mice on Control diet. (Table 4A).

10

3.1.4. KD enhanced E4 metabolic profile compared to controls.
Diet group comparisons within the E4 groups revealed KD induced a significant
increase in cortical concentrations of glutamate, glutamine, GABA, dopamine, serotonin,
and malate (Table 4B), suggesting the KD did indeed counteract APOE4-associated
metabolic deficits. Among the E3 mice, KD significantly reduced cortical levels of many
carbohydrate metabolic intermediates (DHAP, PEP, lactate, UPD-glucose, and UDPgalactose), possibly indicative of a metabolic shift away from carbohydrates in the E3KD mice (Table 4B). Interestingly, E3-KD mice had reduced levels of both reduced and
oxidized glutathione, which could mean antioxidant dysfunction or simply higher
mitochondrial efficiency and a reduced need for ROS mitigation.
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Table 4. KD effects on cortical metabolite concentrations. (A) Genotype effects
in Control groups show reduced metabolite levels in E4-Ctrl; KD comparisons
showed recovery in TCA cycle metabolites for E4 mice. (B) KD enhanced both
E3 and E4 metabolic profile compared to respective controls.

Table 4A

Super
Pathway

Sub Pathway

Alanine and
Aspartate
Metabolism
Amino Acid

Glutamate
Metabolism
Glutathione
Metabolism

Carbohydrate

Energy

Glycolysis,
Gluconeogenesis,
and Pyruvate
Metabolism

TCA Cycle

Biochemical Name

ANOVA
Contrasts - Fold
of Change
E4
E3
Control

Keto

aspartate
N-acetylaspartate (NAA)
asparagine
glutamate
glutamine
N-acetyl-aspartyl-glutamate
(NAAG)
gamma-aminobutyrate (GABA)
glutathione, reduced (GSH)
glutathione, oxidized (GSSG)
phosphoenolpyruvate (PEP)

0.79
1.10
0.80
0.77
0.68

0.91
1.17
0.91
1.17
1.01

0.86

0.97

0.63
0.87
1.01
0.89

0.94
1.76
1.11
1.19

pyruvate

1.14

1.38

citrate
aconitate [cis or trans]

0.68
0.64

0.84
0.80

isocitrate
succinylcarnitine (C4-DC)

0.61
0.78

0.81
1.27

succinate
fumarate

0.35
0.68

1.04
0.79

malate

0.68

0.93
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Table 4A
Fatty Acid
Metabolism
Long Chain
Saturated Fatty
Acid
Long Chain
Polyunsaturated
Fatty Acid (n3 and
n6)
Lipid

Carnitine
Metabolism
Ketone Bodies
Neurotransmitter
Phospholipid
Metabolism
Glycerolipid
Metabolism
Sterol

acetyl CoA

0.92

1.40

palmitate (16:0)
stearate (18:0)
arachidate (20:0)
eicosapentaenoate (EPA;
20:5n3)
linoleate (18:2n6)
arachidonate (20:4n6)

0.84
0.85
0.84

0.68
0.67
0.69

0.92

0.49

1.13
0.84

0.51
0.87

carnitine

0.89

1.03

3-hydroxybutyrate (BHBA)
acetylcholine

1.01
0.83

0.70
1.35

choline
choline phosphate

0.98
0.97

0.95
0.95

glycerophosphoethanolamine

0.82

1.08

glycerol

0.83

0.96

cholesterol sulfate

1.29

0.98
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Table 4B

Super Pathway Sub Pathway

Glycine, Serine
and Threonine
Metabolism
Glutamate
Metabolism
Tyrosine
Metabolism
Amino Acid

Tryptophan
Metabolism
Methionine,
Cysteine, SAM
and Taurine
Metabolism
Urea cycle;
Arginine and
Proline
Metabolism
Glutathione
Metabolism

Carbohydrate

Glycolysis,
Gluconeogenesis,
and Pyruvate
Metabolism
Nucleotide Sugar

Energy

TCA Cycle

Biochemical Name

ANOVA
Contrasts Fold of
Change
Keto
Control

E3

E4

N-acetylglycine

1.46

1.62

glutamate
glutamine
gamma-aminobutyrate (GABA)
tyrosine
dopamine

0.91
0.96
0.95
1.21
0.85

1.38
1.43
1.41
1.07
1.63

serotonin

0.79

1.21

hypotaurine

1.13

0.74

taurine

0.85

0.91

urea

0.65

0.95

glutathione, reduced (GSH)
glutathione, oxidized (GSSG)
dihydroxyacetone phosphate (DHAP)
phosphoenolpyruvate (PEP)

0.57
0.82
0.82
0.78

1.14
0.90
1.06
1.05

lactate

0.86

0.98

UDP-glucose

0.66

0.98

UDP-galactose
malate

0.73
0.93

1.20
1.27

2-methylcitrate/homocitrate

1.35

1.22
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3.1.5. KD modulates brain physiology (vasculature and white matter myelination).
DTI is emerging as a novel imaging technique for indexing neuronal changes in white
matter during AD development. Using this MRI technique, it has been well established
that white matter damage accumulates during AD (Bozzali et al., 2002), however, the
impact of APOE4 on white matter is less well characterized. We noted significant
genotype differences in corpus callosum (CC) fraction anisotropy (FA) measurements
taken via DTI scans (F (1,68) = 10.80; p = 0.0016; Fig. 3A). Post-hoc analysis showed
enhanced white matter integrity in E3-Ctrl over E4-Ctrl (p = 0.0085) and E3-KD over
E4-KD (p = 0.0085), suggesting the APOE4 allele may disrupt white matter integrity in a
region-specific manner. We observed significant diet effects in averaged External
Capsule (EC) FA values (F (1,68) = 5.558; p = 0.0213; Fig. 3B). Post-hoc analysis did
not reveal further significant comparisons between groups. Lastly, we noticed significant
genotype effects present in averaged Fimbria FA values (F (1,68) = 9.179; p = 0.0035;
Fig. 3D). Post-hoc analysis revealed enhanced E3-Ctrl (p = 0.0178) and E3-KD (p =
0.0178) white matter integrity when compared to respective E4 diet groups, again,
indicating an APOE4-related disruption of white matter integrity.
Arterial Spin Labeling (ASL) is another MRI technique used to assess tissue
perfusion, or CBF. Previous research in AD has revealed global CBF reductions of up to
20% in AD patients compared to nondemented controls (Roher et al., 2012). Studies
investigating APOE4 effects on CBF report that changes in CBF are largely determinant
on age, and that hypoperfusion is generally seen in elderly APOE4 carriers compared to
age-matched noncarriers, though this reduction is not always observed in younger E4
carriers (Hogh et al., 2001; Tai et al., 2016). Lastly, the KD has been shown to increase
rCBF in young, wildtype (WT) mice (Ma et al., 2018).Our results indicated a significant
effect of diet on average CBF of the left and right hippocampi (F (1,57) = 4.654; p =
0.0352; Fig. 3G). However, post-hoc analysis showed no significant individual
comparisons. We did not observe any significant differences in CBF for the whole brain,
cortex, or thalamus, though there is a noticeable trend of lower rCBF for Control mice
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relative to respective KD mice. These results are not unexpected – the mice in this study
were young and aging is a very large factor in CBF changes.

Figure 3. KD and APOE genotype modulate DTI and CBF measures. FA
values for (A) corpus callosum, (B) averaged left and right external capsule, (C)
averaged internal capsule, and (D) averaged fimbria. CBF values for (E) whole
brain (global), (F) cortex, (G) averaged hippocampi, and (H) averaged
thalamus. * p < 0.05; ** p < 0.01.
3.1.6. KD increased beneficial SCFA levels in plasma of KD mice.
Previous research points to a KD-induced increase in SCFA production mediated
through changes in gut microbiota composition (Ma et al., 2018; Paoli et al., 2019).
SCFAs possess neuroactive properties, such as enhancing blood-brain barrier (BBB)
integrity, functioning as an alternative cellular energy source, increasing neurotransmitter
reserves, modulating gene expression, and improving memory consolidation (Morrison
and Preston, 2016; Silva et al., 2020). In addition to CNS benefits, SCFAs also provide
an alternative fuel source to enterocytes, hepatocytes, and other peripheral tissues,
influence cellular signaling and gene expression, and have even been shown to regulate
16

appetite, sleep, and immune system function (Morrison and Preston, 2016; Silva et al.,
2020). We observed markedly significant diet effects on plasma acetic acid
concentrations (F (1,54) = 158.8; p < 0.0001; Fig. 4A). Post-hoc analysis showed
significantly elevated plasma acetic acid levels in both E3-KD (p < 0.0001) and E4-KD
(p < 0.0001) compared to respective controls. Conversely, we observed a nonsignificant
diet effect resulting in reduced acetic acid production in the cecum of E3-KD and E4-KD
mice compared respective controls (F (1,55) = 0.7349; p = 0.3950; Fig. 4B).
We observed significant APOE genotype effects on plasma butyric acid
concentrations (F (1,50) = 4.404; p = 0.0409; Fig. 4C). However, post-hoc analysis
showed no significant comparisons existed between the different genotypes. Contrarily,
we found significant diet effects on butyric acid production within the cecum (F (1,56) =
4.430; p = 0.0398; Fig. 4D). Post-hoc analysis showed no significantly different
comparisons between groups for this measure.
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Figure 4. KD and APOE genotype effects on plasma and cecum SCFA levels.
(A) KD significantly increased E3-KD and E4-KD plasma levels of acetic acid
compared to respective controls. (B) KD slightly reduced E3-KD and E4-KD
acetic acid production in cecum compared to respective controls. (C) APOE
genotype had significant influence on plasma butyric acid levels for E3-KD and
E4-KD comparison, although no individual comparisons were noted. (D) KD
significantly reduced butyric acid production in cecum, though no significant
comparisons were detected.
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3.1.7. APOE genotype more strongly influenced alpha diversity within the gut
microbiome than diet.
As mentioned above, the APOE4 allele produces alterations in gut microbiome
composition and diversity, leading to sustained gut dysbiosis. This chronic dysbiosis is
thought to contribute to the pathogenesis of Alzheimer’s disease through disrupting BBB
integrity, impairing Aβ clearance and CBF, and increased systemic and cerebral
inflammation (Bostanciklioglu, 2019; Tran et al., 2019; Zajac et al., 2022). In line with
this, we identified significant APOE genotype effects in alpha diversity (Shannon index)
within the gut microbiome of E3 and E4 mice (F (1,53) = 6.992; p = 0.0107; Fig. 5A).
However, post-hoc analysis did not identify any significant comparisons between the
groups. Previous studies have shown the KD increases alpha diversity in WT mice (Ma et
al., 2018), though our results do not show any significant effects of diet on alpha
diversity.
3.1.8. APOE genotype mediated KD alterations to gut microbial profile.
Similar to a previous study (Ma et al., 2018), we observed significant diet effects on
beta diversity in both the E3 and E4 comparisons, though the strength of the diet effects
seems to be modulated based on genotype (Bray-Curtis index; Fig. 5B, 5C). KD
engendered significant dissimilarity between E3-KD and E3-Ctrl gut microbial profiles
(F (1,53) = 6.852; p = 0.001; Fig. 5B) and the E4-KD and E4-Ctrl gut microbial profiles
(F (1,53) = 2.949; p = 0.011; Fig. 5C).

Figure 5. KD and APOE genotype effects on alpha- and beta-diversity. (A) KD
reduced alpha diversity in E3-KD compared to E3-Ctrl, and in E4-Ctrl
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compared to E3-Ctrl. KD significantly altered beta diversity in both (B) APOE3
and (C) APOE4 mice. * p < 0.05; ** p < 0.01; *** p < 0.001.
3.1.9. KD enhanced microbiome composition by promoting Firmicutes proliferation
and impeding Bacteroidetes growth.
KD alterations in gut microbial composition have not been well characterized. To
further analyze KD effects on the gut microbiome, we investigated the concentrations of
phyla Firmicutes, Bacteroidetes, and Proteobacteria. We found that diet significantly
affected the Firmicutes:Bacteroidetes (F:B) phyla ratio (F (1,50) = 7.585; p = 0.0082;
Fig. 6A). Post-hoc analysis showed no significant differences among group comparisons.
Additionally, we observed significant diet effects on relative abundance of microbiota
comprising phyla Firmicutes (F (1,56) = 7.233; p = 0.0094; Fig. 6B). Once more, posthoc analysis showed no significant differences among group comparisons. Lastly, we
observed significant diet effects on relative abundance of microbiota belonging to phyla
Bacteroidetes (F (1,56) = 15.58; p = 0.0002; Fig. 6C). Post-hoc analysis revealed
significantly decreased relative abundance of Bacteroidetes in E3-KD microbial profile
compared to E3-Ctrl (p = 0.0080).
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Figure 6. KD effects on relative abundance of microbial phyla Firmicutes,
Bacteroidetes, and Proteobacteria. (A) KD affected the F:B ratio in E3 and E4
comparisons. (B) KD influenced Firmicutes relative abundance within the
gastrointestinal tract. (C) KD influenced Bacteroidetes relative abundance
within the gastrointestinal tract. (D) KD reduced Proteobacteria relative
abundance within the gastrointestinal tract. * P < 0.05; ** p < 0.01.
3.1.10. KD cultivated similar microbial colonies within the gut of E3 and E4 mice
compared to bacterial colonies within mice fed control diet.
A LEfSe analysis allows us to examine any significant changes in relative abundances
among bacterial species due to KD intervention. The analysis revealed significantly
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higher relative abundance of Lactobacillus johnsonii and L. reuteri within both E3-KD
and E4-KD relative to respective controls. We also observed that Ctrl mice microbiome
composition matched each other far more closely than KD mice microbial communities
did. However, the few species in common among the KD mice are associated with
beneficial health effects.

Figure 7. KD effects on microbial profile similarity. The LEfSe figure illustrates
species of significantly different relative abundance between (A) E3-Ctrl and
E3-KD and (B) E4-Ctrl and E4-KD.
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3.2.

Sex Effects

3.2.1. KD reduced weight gain in all groups relative to controls, excepting the APOE3
females.
We observed significant diet effects for body weight measurements, but no genotype
or sex effects. (Table 5). Post-hoc analysis revealed the E4-Ctrl males had significantly
body weight gain than the E4-KD males (p = 0.0011).
We also discovered diet and sex effects present for caloric consumption over week 6
(F (1,53) = 16.52; p = 0.0002), week 10 (F (1,51) = 36.01; p < 0.0001), week 14 (F (1,48)
= 29.36; p < 0.0001), and week 16 (F (1,52) = 12.07; p = 0.0010; data not shown).
Table 5. KD reduces weight gain for all groups except APOE3 Females. A
three-way ANOVA showed significant diet effects (F (1,71) = 13.88; p =
0.0004), but no significant effects on genotype or sex. Post-hoc analysis
revealed significantly reduced weight for E4-KD mice relative to E4-Ctrl (p =
0.0011).
Genotype

APOE3 Male

APOE3 Female

APOE4 Male

APOE4 Female

Control Diet

38.13 ± 2.48

32.88 ± 4.16

39.56 ± 2.75

34.30 ± 6.26

Ketogenic Diet

32.86 ± 4.12

32.89 ± 6.41

30.30 ± 4.12

32.62 ± 5.62

3.2.2. Diet and genotype both strongly modulated blood ketone body concentration,
while diet and sex both strongly influenced blood glucose concentrations.
We noted no significant sex effects present in ketone body concentration, though we
detected very strong diet effects (F (1,51) = 41.40; p < 0.0001; Fig. 8C). However, posthoc analysis revealed significantly increased ketone body levels in E4-KD males over
E4-KD females (p = 0.0006), showing the presence of sex effects in at least one
comparison. Additionally, post-hoc analysis showed increased ketone body levels in both
E3-KD males (p = 0.0017) and E4-KD males (p = 0.0003) when compared to respective
male control counterparts; there were no significant differences between female E3-KD
vs. E3-Ctrl or female E4-KD vs E4-Ctrl. Lastly, post-hoc analysis indicated significantly
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increased ketone body levels in E3-KD females compared to E4-KD females (p =
0.0152).
We recorded significant diet effects (F (1,44) = 5.249; p = 0.0268) and markedly
significant sex effects (F (1,44) = 19.83; p < 0.0001; Fig. 8D) in blood glucose levels.
Post-hoc analysis did not reveal any significant differences upon further group
comparisons.

Figure 8. KD, APOE genotype, and sex effects on blood glucose and ketone
body levels. (A) Sex, diet, and genotype influence blood ketone body levels.
(B) Sex and diet effects modulated blood glucose levels.

3.2.3. KD intervention induced remarkable metabolic function recovery in E4 females
compared to controls.
We observed massive KD-induced recovery in levels of crucial metabolites within
cortical tissues of E4-KD females compared to E4-Ctrl females (Table 6). Metabolites
that were significantly elevated in E4-KD females include NAA, multiple
neurotransmitters (glutamate, glutamine, GABA, dopamine, and serotonin), along with
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many TCA cycle intermediates (citrate, aconitate, isocitrate, alpha-ketoglutarate,
succinylcarnitine, succinate, and malate). This KD enhancement was not seen among E4
males, E3 females and E3 males (Table 6).
We also compared metabolic profiles of E4-Ctrl females to E3-Ctrl females to
determine baseline metabolic function between females of different genotypes (Table 6).
This comparison revealed the E4 mice had significantly lower levels of almost all
metabolites mentioned earlier (glutamate, glutamine, GABA, citrate, aconitate, isocitrate,
alpha-ketoglutarate, succinylcarnitine, succinate, and malate). The only metabolites that
were not significantly reduced at baseline were dopamine and serotonin. Interestingly, we
also found that NAA was significantly elevated in E4-Ctrl females compared to E3-Ctrl
females, as it was in E4-KD females over E4-Ctrl females.
Table 6. KD effects on cortical metabolite concentrations. Sex effects were
markedly prevalent in E4 female mice, revealing massive recovery of metabolic
profile in E4-KD females compared to respective controls.
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Amino Acid

Super
Pathway

Carb.

M Ctrl

E4 F

E4 M

E3 F

E3 M

E4/E3

E4/E3

Keto/Ctrl

Keto/Ctrl

Keto/Ctrl

Keto/Ctrl

1.36

0.98

1.19

1.01

0.96

1.01

0.36

1.13

3.36

0.80

1.01

0.85

glutamine
gammaaminobutyrate
(GABA)

0.29

1.10

3.18

0.90

1.00

0.95

0.24

1.13

3.33

0.84

1.06

0.84

dopamine

0.50

0.57

3.11

1.20

0.80

0.84

serotonin

0.78

0.73

2.19

1.00

0.86

0.74

ribose 1phosphate

1.41

0.91

1.19

0.92

0.79

0.92

citrate
aconitate [cis
or trans]
isocitrate
alphaketoglutarate
Succinylcarnit
ine
(C4-DC)
succinate

0.38

1.11

1.93

0.83

1.18

0.76

0.38

1.01

1.83

0.83

1.17

0.73

0.37

0.97

1.76

0.82

1.09

0.66

0.50

1.33

3.18

0.65

1.45

1.01

0.35

1.11

3.37

0.56

0.74

0.70

0.22

0.42

5.25

1.36

0.80

0.76

malate

0.42

0.99

1.92

0.92

0.94

0.95

Biochemical
Name

Alanine and
Aspartate
Metabolism

Nacetylaspartate
(NAA)
glutamate

Glutamate
Metabolism
Tyrosine
Metabolism
Tryptophan
Metabolism

Energy

F Ctrl

Sub
Pathway

Pentose
Phosphate
Pathway

TCA Cycle

3.2.4. Genotype effects modulated DTI measurements more than sex or diet. Diet
effects influenced CBF in the hippocampus and thalamus.
We noted significant genotype differences in corpus callosum (CC) fraction
anisotropy (FA) measurements taken via DTI scans (F (1,63) = 8.626; p = 0.0046; Fig.
9A). did not reveal further significant comparisons between groups. We observed
significant diet effects in averaged External Capsule (EC) FA values (F (1,63) = 5.705; p
= 0.0199; Fig. 9B). Post-hoc analysis did not reveal further significant comparisons
between groups. We noted significant genotype (F (1,63) = 5.335; p = 0.0242) and sex
effects (F (1,63) = 4.564; p = 0.0365; Fig. 9C) for averaged internal capsule (IC) FA
values. Post-hoc analysis revealed E3-KD male mice had enhanced white matter integrity
over both E4-KD males (p = 0.0386) and E3-KD females (p = 0.0029). Lastly, we
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noticed significant genotype effects present in averaged Fimbria FA values (F (1,63) =
10.37; p = 0.0020; Fig. 9D), though post-hoc analysis did not show further significant
comparisons.
We observed significant diet effects in CBF of averaged left and right hippocampi (F
(1,52) = 4.994; p = 0.0298; Fig. 9G). However, post-hoc analysis showed no significant
individual comparisons. We also noted significant diet effects for averaged thalami CBF
values (F (1,52) = 4.133; p = 0.0472; Fig. 9H). We did not observe any significant
differences in CBF for the whole brain or cortex.

Figure 9. Sex effects in DTI and CBF measures. FA values for (A) corpus
callosum, (B) averaged left and right external capsule, (C) averaged internal
capsule, and (D) averaged fimbria. CBF values for (E) whole brain (global), (F)
cortex, (G) averaged hippocampi, and (H) averaged thalamus. * p < 0.05; ** p
< 0.01.
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3.2.5. Sex and diet heavily modified SCFA production and transport.
We observed significant genotype effects only in plasma butyric acid levels (F (1,48)
= 6.619, p = 0.0132, Fig. 10A). Post-hoc analysis revealed significantly elevated plasma
butyric acid in E4-KD females compared to E3-KD females (p = 0.0063; Fig. 10A). We
noted significant diet effects in plasma acetic acid levels (F (1,48) = 113.6; p < 0.0001;
Fig. 10B). Post-hoc analysis showed elevated plasma acetic acid across all groups for E3KD males (p = 0.0005), E3-KD females (p = 0.0004), E4-KD males (p < 0.0001), and
E4-KD females (p < 0.0001) compared to respective controls (Fig. 10B). We observed
significant sex effects influenced plasma propionic acid levels (F (1,45) = 6.292; p =
0.0158; Fig 7C). Post-hoc analysis did not show any specific significant differences
between groups. We noted significant diet effects (F (1,46) = 13.42; p = 0.0006),
genotype effects (F (1,46) = 5.305; p = 0.025), and sex effects (F (1,46) = 7.612; p =
0.0063) in plasma valeric acid levels (Fig. 10D). Post-hoc analysis revealed the E4-KD
females drove these effects; plasma acetic acid was significantly elevated in E4-KD
females compared to E4-Ctrl females (p < 0.0001), E3-KD females (p = 0.0161), and E4KD males (p = 0.0008; Fig. 10D).
We also analyzed the contents of the cecum to identify differences in SCFA
production and formation. We noted significant diet effects (F (1,51) = 10.98; p =
0.0017), genotype effects (F (1,51) = 7.213; p = 0.0097), and sex effects (F (1,51) =
73.18; p < 0.0001; Fig. 10E) in levels of cecal butyric acid. Post-hoc analysis of cecal
butyric acid revealed significantly increased production in the cecum of E3-KD males (p
= 0.0242) and E4-KD males (p = 0.0016) compared to respective controls. Post-hoc
analysis of cecal butyric acid also showed significantly increased production in E3-Ctrl
males (p < 0.0001), E3-KD males (p = 0.0145), and E4-Ctrl males (p < 0.0001) compared
to respective female groups. We did not see significant differences for cecal butyric acid
between specific genotype comparisons.
We observed the presence of significant diet effects ((F (1,51) = 4.266; p = 0.0440),
genotype effects ((F (1,51) = 7.213; p = 0.0199), and sex effects (F (1,51) = 95.15; p <
0.0001; Fig. 10F) for acetic acid levels in the cecum. Post-hoc analysis of diet effects
showed E4-KD males had significantly increased acetic acid relative to E4-Ctrl males (p
= 0.0192). No significant genotype comparisons were found during post-hoc analysis,
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however, post-hoc analysis of sex effects revealed significantly increased acetic acid in
cecum of E3-Ctrl males (p < 0.0001) and E3-KD males (p < 0.0001) relative to respective
female groups. We also observed a significant increase in E4-Ctrl males relative to E4Ctrl females (p = 0.0001).
We noted significant genotype effects (F (1,49) = 6.578; p = 0.0134) and sex effects
(F (1,49) = 35.56; p < 0.0001; Fig. 10G) for levels of cecum propionic acid. Post-hoc
analysis showed no significant genotype comparisons, though analysis of the sex effects
showed increased cecum acetic acid in E3-Ctrl males (p = 0.0010) and E3-KD males (p =
0.0005) relative to respective female groups.

Figure 10. Sex effects on plasma and cecum SCFA levels. The top panels, from
left to right, display (A) plasma butyric acid levels, (B) plasma acetic acid
levels, and (C) plasma propionic acid levels in diet and genotype groups
stratified by sex. The bottom panels, from left to right, display (D) cecum
butyric acid levels, (E) cecum acetic acid levels, and (F) cecum propionic acid
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levels in diet and genotype groups stratified by sex. * p < 0.05; ** p < 0.01; ***
p < 0.001; **** p < 0.0001.
3.2.6. Sex disparately altered gut microbial species diversity in E4 male and female
mice.
We noted the presence of significant diet effects (F (1,52) = 5.171; p = 0.0271) and
significant genotype effects (F (1,52) = 9.713; p = 0.0030) in alpha diversity (Shannon
index; Fig. 11A). Although sex effects were not significant in the ANOVA test, post-hoc
analysis showed significantly increased diversity in E4-Ctrl males compared to the E4Ctrl females (p = 0.0066, Fig. 11A). Post-hoc analysis also revealed significantly
increased diversity in E3-Ctrl females compared to E4-Ctrl females (p = 0.0001; Fig.
11A).
We observed significant sex effects present for beta diversity measures of gut
microbial dissimilarity (Bray-Curtis index) between both E3-Ctrl males and females (F
(1,60) = 2.430; p = 0.034; Fig. 11B) and between E3-KD males and females (F (1,60) =
2.238; p = 0.049; Fig 8C). We also observed significant dissimilarity between E4-Ctrl
male and female gut microbiota (F (1,60) = 3.622; p = 0.006; Fig. 11D), but not between
the E4-KD male and female gut microbiome (Fig. 11E).
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Figure 11. Sex effects on alpha and beta diversity. (A) Alpha diversity (Shannon
index) was reduced in E4-Ctrl females. Beta diversity (Bray-Curtis index)
comparisons revealed significant dissimilarity between the gut microbial
communities of (B) E3-Ctrl males and females, (C) E3-KD males and females,
and (D) E4-Ctrl males and females. E4-KD males and females did not have
significant dissimilarity in the gut microbiome. * p < 0.05; ** p < 0.01; *** p <
0.001.
3.2.7. Sex contributed to differences between gut microbial profiles in both E3 and E4
mice.
We observed significant sex effects between E3-KD, E3-Ctrl and E4-KD groups (Fig.
12A, 12B, 12C, respectively). We found that, in the E3 groups, the males and females
had significantly dissimilar gut microbiomes; an effect that diet did not normalize
between the different sexes. The E3-KD males had significantly different gut microbial
profiles when compared to E3-KD females (Fig. 12A; p < 0.05), as did the E3-Ctrl males
compared to E3-Ctrl females (Fig. 12B; p < 0.05). Contrarily, we found significant
dissimilarity between the E4-Ctrl male and female gut microbiota populations only (Fig.
12C; p < 0.01). The KD diet reduced this sex difference below significance.
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Figure 12. Sex effects on gut microbial composition. The LEfSe figures display
microbial species that were significantly different between sexes for groups (A)
E3-KD, (B) E3-Ctrl, and (C) E4-Ctrl.
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Table 7. Results summary table.
Parameter
Body weight
Caloric
intake
Blood
Glucose Levels

APOE3-KD

APOE4-KD

Similar reductions in body weight
Similar increases in caloric intake
Reduced glycolysis (or reduced glucose levels)

Blood
Induced ketogenesis

Ketone Body
Levels
SCFA’s
Gut
Microbiome

Enhanced short chain fatty acid production
Increases in Firmicutes relative to Bacteriodetes

Alpha

KD normalized alpha diversity

Diversity
Beta
Diversity
Microbiome
LEfSe

KD did not normalize beta
diversity

KD normalized beta diversity

KD promoted healthier microbial species growth
4. DISCUSSION

This study provides evidence for the KD as a preventative therapy for AD in young
APOE3 and APE4 male and female transgenic mouse models. Specifically, KD
intervention in young male and female APOE transgenic mice can decrease body weight,
reduce glucose utilization, enhance TCA cycle flux and antioxidant protection, restore
brain metabolites involved in neurotransmitter synthesis and neuronal integrity,
normalize fatty acid levels, and enhance short chain fatty acid production, utilization, and
exportation to periphery. Furthermore, we show that KD beneficially alters the gut
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microbiome by promoting the growth of healthy microbial species, and normalizing alpha
and beta diversity.
The APOE4 allele increases risk for sporadic AD in part due to the pathological
metabolic and vascular deficits that arise decades before the onset of clinical symptoms
(2021). One mechanism through which these pathological changes are thought to
contribute to AD development is by promoting systemic dysregulation of energy
homeostasis, resulting in chronic cellular energy deficit that leads to increased reactive
oxygen species (ROS), inflammation, and cell death (de la Monte and Tong, 2014). In
line with this, we report evidence of a dysregulated metabolism in APOE4 mice fed a
control diet relative to APOE3 mice fed the same diet: E4-Ctrl mice had significantly
reduced cortical levels of most primary TCA cycle intermediates and several amino acids
and their intermediates, such as neurotransmitters GABA, glutamate, and glutamine. The
E4-Ctrl mice also had significantly increased cortical levels of oxidized glutathione, a
biomarker of high mitochondrial oxidative stress, relative to the E3-Ctrl mice.
Myelination also appeared to be subject to genotype effects, as E4-Ctrl mice displayed
significantly reduced myelin content in the corpus callosum and fimbria relative to E3Ctrl mice, as shown by DTI scan. The E4 allele is thought to contribute to demyelination,
potentially through interaction with the mammalian Target of Rapamycin (mTOR)
protein complex, though the full mechanisms are unknown. We also report similar
weights between the E4-Ctrl and E3-Ctrl groups. Prior studies have shown APOE4-TR
mice have reduced weight on chow diets relative to APOE3-TR mice (Huebbe et al.,
2015; Lane-Donovan and Herz, 2016), though this difference appears to increase with
age. Our study investigated the effects of dietary intervention on young mice (~9 months
old at sacrifice), which could explain the differing results.
It is also becoming increasingly clear that, in addition to genetic risk factors like the
E4 allele, modifiable lifestyle factors such as diet and exercise can also contribute to or
reduce the risk of sporadic AD (Norwitz et al., 2021). The KD dietary intervention in
APOE4-TR mice significantly improved the metabolic dysregulation seen in E4 mice –
we report increases in E4-KD cortical amino acid metabolites, including
neurotransmitters GABA, glutamine, and glutamate, along with a normalization of TCA
cycle intermediates and the antioxidant glutathione pool relative to E4-Ctrl mice. We also
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report a significant weight reduction and significant plasma ketone body levels in E4-KD
mice relative to E4-Ctrl. Previous studies in both APOE-TR and wildtype (WT) mice
have similarly shown KD-induced reductions in weight (Lane-Donovan and Herz, 2016;
Ma et al., 2018) and increases in plasma ketone bodies (Ma et al., 2018). Further diet
effects from KD intervention include significant increases in plasma SCFA’s (butyric
acid, acetic acid), along with significant increases in Firmicutes, a phyla consisting of
species known to produce SCFA’s, such as Lactobacillus (Ma et al., 2018). Lastly, we
report a significant shift in gut microbial community composition (β-diversity, BrayCurtis index) driven by KD intervention in E4 mice relative to E4 mice on control die. A
similar study in young, WT mice also reports a KD-induced shift in the gut microbial
community (Ma et al., 2018).
We also report a similar metabolic enhancement in APOE3 mice fed the KD, relative
to E3 mice fed a Control diet. Notably, we report a reduction in multiple carbohydrate
and amino acid metabolic intermediates in the cortices of E3-KD mice relative to E3-Ctrl,
where the reverse was true among the E4 comparison. On the other hand, KD altered the
E3 gut microbial community more robustly than it did for the E4 mice, though both the
E3-KD and E4-KD had significantly dissimilar gut composition relative to respective
controls. Although, the E3-KD did experience significantly enhanced F:B ratio relative to
E3-Ctrl, as well as significantly increased relative abundance of Bacteroidetes spp.,
Firmicutes spp., and Proteobacteria spp.
There is a profound lack of research focusing on the interaction between APOE and
sex, especially considering our results. E4 female mice experienced remarkable recovery
from KD intervention in a variety of health parameters, including metabolomics, gut
microbiome, plasma SCFA’s, and CBF. The E4 male mice and E4 female mice
experienced similar improvements from KD intervention, though females displayed a far
more robust response to the KD. The results of this study allude to an interplay between
APOE genotype and sex that can affect many various aspects of health, especially gut
microbiome composition and energy metabolism. The results are broken down into two
separate sections. The first section focuses only on diet and genotype effects, and the
results indicate that the KD diet was beneficial to both E3 and E4 mice; while the health
improvements to E3 were minimal, the E4 mice had considerable restoration of health
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measures with KD intervention. The second section further splits the data to include sex,
and this reveals that the E4 female mice suffer the most from APOE4-associated health
deficits. However, again, incredible restoration of health measures is seen with KD
intervention. In summary, our results demonstrate three key findings: 1) the E4 allele
presents a multifaceted detrimental phenotype in both males and females, 2) this negative
health phenotype is more pronounced in females than in males, and 3) the KD can help
restore the phenotype regardless of sex, and even improve the comparatively healthier E3
phenotype.
This study is not without its limitations. The main limitation is the relatively small
sample size, especially of the E4 female cohort, which became a stronger focus of this
study than expected. Due to the exploratory nature of our study, we chose to focus on KD
effects in young mice, even though a more aged study population would have very likely
increased significances between comparisons. However, our findings offer a priori
hypotheses to be tested in more expansive, future studies. Other studies focusing on
dietary intervention in APOE-TR mice accounted for homozygotic and heterozygotic
APOE status (Lane-Donovan and Herz, 2016). We did not consider zygosity for the
human/wildtype APOE alleles, thus, we are unable to determine how significantly
zygosity contributed to the results. Another important limitation is that we failed to
control for a fed or fasted state prior to MRI scans or tissue collection. The difference
between metabolite concentrations, SCFA production and utilization, CBF, gut
microbiome and other many other measures depend heavily on energetic status and may
fluctuate immensely as the body changes from one nutritional state to the other,
potentially affecting results.
Future research focusing on dietary and lifestyle interventions for early AD
prevention should seek to elucidate the specific mechanisms of peripheral and neuronal
APOE response to a ketogenic diet, along with other dietary and lifestyle interventions.
An emphasis should be placed on specific gene expression profiles involved in metabolic
function, especially in relation to sex chromosomal influences on metabolism. Peripheral
and CNS APOE expression differ relative to each other and respond to dietary and
lifestyle habits through an interplay between the two distinct pools, thus, future research
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should investigate the pathways through which these related APOE pools interact and
how strongly they can influence each other.
In this study, we detail how a dietary intervention with KD can effectively alter the
gut microbiome in a young, transgenic AD mouse model, enhance neural metabolic
functions and sustain a healthy body weight. We focus on the underlying metabolic
features contributed by the APOE4 genotype, the largest genetic risk factor for the
development of AD and show how KD intervention can help mitigate APOE4-related
health deficits. This represents a shift in AD research, from the amyloid hypothesis to the
metabolic features underlying the disease. As impairment of energy metabolism and
elevation of neuroinflammation are well-established features of AD, a nutritional
approach that engenders a fundamental shift in systemic metabolism could provide a
viable strategy to reverse the E4-related health risks and prevent the onset of the disease.
Understanding the dietary effects in the context of the gut-brain axis may have significant
future implications for preventing AD in asymptomatic APOE4 carriers.
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APPENDIX
Metabolon Platform
Sample Accessioning: Following receipt, samples were inventoried and immediately
stored at -80oC. Each sample received was accessioned into the Metabolon LIMS system
and was assigned by the LIMS a unique identifier that was associated with the original
source identifier only. This identifier was used to track all sample handling, tasks, results,
etc. The samples (and all derived aliquots) were tracked by the LIMS system. All portions
of any sample were automatically assigned their own unique identifiers by the LIMS when
a new task was created; the relationship of these samples was also tracked. All samples
were maintained at -80oC until processed.
Sample Preparation: Samples were prepared using the automated MicroLab STAR®
system from Hamilton Company. Several recovery standards were added prior to the first
step in the extraction process for QC purposes. To remove protein, dissociate small
molecules bound to protein or trapped in the precipitated protein matrix, and to recover
chemically diverse metabolites, proteins were precipitated with methanol under vigorous
shaking for 2 min (Glen Mills GenoGrinder 2000) followed by centrifugation. The
resulting extract was divided into five fractions: two for analysis by two separate reverse
phase (RP)/UPLC-MS/MS methods with positive ion mode electrospray ionization (ESI),
one for analysis by RP/UPLC-MS/MS with negative ion mode ESI, one for analysis by
HILIC/UPLC-MS/MS with negative ion mode ESI, and one sample was reserved for
backup. Samples were placed briefly on a TurboVap® (Zymark) to remove the organic
solvent. The sample extracts were stored overnight under nitrogen before preparation for
analysis.
QA/QC: Several types of controls were analyzed in concert with the experimental
samples: a pooled matrix sample generated by taking a small volume of each experimental
sample (or alternatively, use of a pool of well-characterized human plasma) served as a
technical replicate throughout the data set; extracted water samples served as process
blanks; and a cocktail of QC standards that were carefully chosen not to interfere with the
measurement of endogenous compounds were spiked into every analyzed sample, allowed
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instrument performance monitoring and aided chromatographic alignment. Tables 8 and
9 describe these QC samples and standards. Instrument variability was determined by
calculating the median relative standard deviation (RSD) for the standards that were added
to each sample prior to injection into the mass spectrometers. Overall process variability
was determined by calculating the median RSD for all endogenous metabolites (i.e., noninstrument standards) present in 100% of the pooled matrix samples. Experimental
samples were randomized across the platform run with QC samples spaced evenly among
the injections, as outlined in Figure 13.
Table 8: Description of Metabolon QC Samples
Type
MTRX

Description
Large pool of human plasma
maintained by Metabolon that
has been characterized
extensively.

Purpose
Assure that all aspects of the Metabolon
process are operating within specifications.

Pool created by taking a small
CMTRX aliquot from every customer
sample.
PRCS

Aliquot of ultra-pure water

SOLV

Aliquot of solvents used in
extraction.

Assess the effect of a non-plasma matrix on
the Metabolon process and distinguish
biological variability from process
variability.
Process Blank used to assess the
contribution to compound signals from the
process.
Solvent Blank used to segregate
contamination sources in the extraction.

Table 9: Metabolon QC Standards
Type

Description

RS

Recovery Standard

IS

Internal Standard

Purpose
Assess variability and verify
performance of extraction and
instrumentation.
Assess variability and performance of
instrument.
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1 st injection

Client samples

Study samples randomized and balanced

Final injection

DAY 1
DAY 2
CMTRX: Technical
replicates created from an
aliquot of all client study
samples

CMTRX

Process Blank

Client samples

Figure 13. Preparation of client-specific technical replicates. A small aliquot of each
client sample (colored cylinders) is pooled to create a CMTRX technical replicate sample
(multi-colored cylinder), which is then injected periodically throughout the platform run.
Variability among consistently detected biochemicals can be used to calculate an estimate
of overall process and platform variability.
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Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectroscopy
(UPLC-MS/MS): All methods utilized a Waters ACQUITY ultra-performance liquid
chromatography (UPLC) and a Thermo Scientific Q-Exactive high resolution/accurate
mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and
Orbitrap mass analyzer operated at 35,000 mass resolution. The sample extract was dried
then reconstituted in solvents compatible to each of the four methods. Each reconstitution
solvent contained a series of standards at fixed concentrations to ensure injection and
chromatographic consistency.

One aliquot was analyzed using acidic positive ion

conditions, chromatographically optimized for more hydrophilic compounds. In this
method, the extract was gradient eluted from a C18 column (Waters UPLC BEH C182.1x100 mm, 1.7 µm) using water and methanol, containing 0.05% perfluoropentanoic acid
(PFPA) and 0.1% formic acid (FA). Another aliquot was also analyzed using acidic
positive ion conditions, however it was chromatographically optimized for more
hydrophobic compounds. In this method, the extract was gradient eluted from the same
afore mentioned C18 column using methanol, acetonitrile, water, 0.05% PFPA and 0.01%
FA and was operated at an overall higher organic content. Another aliquot was analyzed
using basic negative ion optimized conditions using a separate dedicated C18 column. The
basic extracts were gradient eluted from the column using methanol and water, however
with 6.5mM Ammonium Bicarbonate at pH 8. The fourth aliquot was analyzed via negative
ionization following elution from a HILIC column (Waters UPLC BEH Amide 2.1x150
mm, 1.7 µm) using a gradient consisting of water and acetonitrile with 10mM Ammonium
Formate, pH 10.8. The MS analysis alternated between MS and data-dependent MSn scans
using dynamic exclusion. The scan range varied slighted between methods but covered
70-1000 m/z. Raw data files are archived and extracted as described below.
Bioinformatics: The informatics system consisted of four major components, the
Laboratory Information Management System (LIMS), the data extraction and peakidentification software, data processing tools for QC and compound identification, and a
collection of information interpretation and visualization tools for use by data analysts.
The hardware and software foundations for these informatics components were the LAN
backbone, and a database server running Oracle 10.2.0.1 Enterprise Edition.
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LIMS: The purpose of the Metabolon LIMS system was to enable fully auditable
laboratory automation through a secure, easy to use, and highly specialized system. The
scope of the Metabolon LIMS system encompasses sample accessioning, sample
preparation and instrumental analysis and reporting and advanced data analysis. All of the
subsequent software systems are grounded in the LIMS data structures. It has been
modified to leverage and interface with the in-house information extraction and data
visualization systems, as well as third party instrumentation and data analysis software.
Data Extraction and Compound Identification: Raw data was extracted, peakidentified and QC processed using Metabolon’s hardware and software. These systems are
built on a web-service platform utilizing Microsoft’s .NET technologies, which run on
high-performance application servers and fiber-channel storage arrays in clusters to
provide active failover and load-balancing. Compounds were identified by comparison to
library entries of purified standards or recurrent unknown entities. Metabolon maintains a
library based on authenticated standards that contains the retention time/index (RI), mass
to charge ratio (m/z), and chromatographic data (including MS/MS spectral data) on all
molecules present in the library. Furthermore, biochemical identifications are based on
three criteria: retention index within a narrow RI window of the proposed identification,
accurate mass match to the library +/- 10 ppm, and the MS/MS forward and reverse scores
between the experimental data and authentic standards. The MS/MS scores are based on a
comparison of the ions present in the experimental spectrum to the ions present in the
library spectrum. While there may be similarities between these molecules based on one
of these factors, the use of all three data points can be utilized to distinguish and
differentiate biochemicals. More than 3300 commercially available purified standard
compounds have been acquired and registered into LIMS for analysis on all platforms for
determination of their analytical characteristics. Additional mass spectral entries have been
created for structurally unnamed biochemicals, which have been identified by virtue of
their recurrent nature (both chromatographic and mass spectral). These compounds have
the potential to be identified by future acquisition of a matching purified standard or by
classical structural analysis.
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Curation: A variety of curation procedures were carried out to ensure that a high
quality data set was made available for statistical analysis and data interpretation. The QC
and curation processes were designed to ensure accurate and consistent identification of
true chemical entities, and to remove those representing system artifacts, mis-assignments,
and background noise.

Metabolon data analysts use proprietary visualization and

interpretation software to confirm the consistency of peak identification among the various
samples. Library matches for each compound were checked for each sample and corrected
if necessary.
Metabolite Quantification and Data Normalization: Peaks were quantified using
area-under-the-curve. For studies spanning multiple days, a data normalization step was
performed to correct variation resulting from instrument inter-day tuning differences.
Essentially, each compound was corrected in run-day blocks by registering the medians to
equal one (1.00) and normalizing each data point proportionately (termed the “block
correction”; Figure 14). For studies that did not require more than one day of analysis, no
normalization is necessary, other than for purposes of data visualization. In certain
instances, biochemical data may have been normalized to an additional factor (e.g., cell
counts, total protein as determined by Bradford assay, osmolality, etc.) to account for
differences in metabolite levels due to differences in the amount of material present in each
sample.
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Figure 14: Visualization of data normalization steps for a multiday platform
run.
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Statistical Methods and Terminology
Statistical Calculations: For many studies, two types of statistical analysis are usually
performed: (1) significance tests and (2) classification analysis.

Standard statistical

analyses are performed in ArrayStudio on log transformed data. For those analyses not
standard in ArrayStudio, the programs R (http://cran.r-project.org/) or JMP are used.
Below are examples of frequently employed significance tests and classification methods
followed by a discussion of p- and q-value significance thresholds.
1. One-way ANOVA
ANOVA stands for analysis of variance. For ANOVA, it is assumed that all
populations have the same variances. One-way ANOVA is used to test whether at
least two unknown means are all equal or whether at least one pair of means is
different. For the case of two means, ANOVA gives the same result as a two-sided
t-test with a pooled estimate of the variance.
An ANOVA uses an F-test which has two parameters – the numerator degrees
of freedom and the denominator degrees of freedom. The degrees of freedom in
the numerator are equal to g – 1, where g is the number of groups. If n is the total
number of observations (n1 + n2), then, the denominator degrees of freedom is equal
to n – g. The F-statistic is the ratio of the between-groups variance to the withingroups variance, hence the higher the F-statistic the more evidence we have that the
means are different.
Often within ANOVA, one performs linear contrasts for specific comparisons
of interest. For example, suppose we have three groups A, B, C, then examples of
some contrasts are A vs. B, the average of A and B vs. C, etc. For single-degree of
freedom contrasts, these give the same result as a two-sided t-test with the pooled
estimate of the variance from the ANOVA and degrees of freedom n – g. Below,
we show the three formulas for A vs. B from a three group design as shown above.
The numerator is same in each case, but the denominator differs by the estimates
of the variances, and the degrees of freedom are different for each (if the theoretical
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assumptions hold, then the contrast has the most power, as it has the largest degrees
of freedom).
Welch’s two-sample t-test

2
𝑠𝑠𝐴𝐴

By t = (𝑥𝑥̅𝐴𝐴 − 𝑥𝑥̅𝐵𝐵 )/�𝑠𝑠𝐴𝐴2 /𝑛𝑛𝐴𝐴 + 𝑠𝑠𝐵𝐵2 /𝑛𝑛𝐵𝐵 , and the degrees of freedom is given by
2
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� 𝐵𝐵 �
𝑛𝑛𝐵𝐵

2

𝑛𝑛𝐵𝐵 −1

�

Two-sample t-test with pooled estimate of variance from A and B
2
𝑡𝑡 = (𝑥𝑥̅𝐴𝐴 − 𝑥𝑥̅𝐵𝐵 )/�𝑠𝑠𝐴𝐴𝐴𝐴
(1/𝑛𝑛𝐴𝐴 +/𝑛𝑛𝐵𝐵 )

2
= �(𝑛𝑛𝐴𝐴 − 1)𝑠𝑠𝐴𝐴2 + (𝑛𝑛𝐵𝐵 − 1)𝑠𝑠𝐵𝐵2 �/(𝑛𝑛𝐴𝐴 + 𝑛𝑛𝐵𝐵 − 2), where the degrees
where 𝑠𝑠𝐴𝐴𝐴𝐴

of freedom is nA + nB – 2.

The contrast from the ANOVA,

where

𝑡𝑡 = (𝑥𝑥̅𝐴𝐴 − 𝑥𝑥̅𝐵𝐵 )/�𝑠𝑠 2 (1/𝑛𝑛𝐴𝐴 +/𝑛𝑛𝐵𝐵 )

𝑠𝑠 2 = �(𝑛𝑛𝐴𝐴 − 1)𝑠𝑠𝐴𝐴2 + (𝑛𝑛𝐵𝐵 − 1)𝑠𝑠𝐵𝐵2 + (𝑛𝑛𝐶𝐶 − 1)𝑠𝑠𝐶𝐶2 �/(𝑛𝑛𝐴𝐴 + 𝑛𝑛𝐵𝐵 + 𝑛𝑛𝐶𝐶 −

3), where the degrees of freedom is given by where the degrees of freedom is nA +
nB + nC – 3.

2. Two-way ANOVA
ANOVA stands for analysis of variance. For ANOVA, it is assumed that
all populations have the same variances. For a two-way ANOVA, three statistical
tests are typically performed: the main effect of each factor and the interaction.
Suppose we have two factors A and B, where A represent the genotype and B
represent the diet in a mouse study. Suppose each of these factors has two levels
(A: wild type, knock out; B: standard diet, high fat diet). For this example, there
are 4 combinations (“treatments”): A1B1, A1B2, A2B1, A2B2. The overall
ANOVA F-test gives the p-value for testing whether all four of these means are
equal or whether at least one pair is different. However, we are also interested in
the effect of the genotype and diet. A main effect is a contrast that tests one factor
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across the levels of the other factor. Hence the A main effect compares (A1B1 +
A1B2)/2 vs. (A2B1 + A2B2)/2, and the B-main effect compares (A1B1 + A2B2)/2
vs. (A1B2 + A2B2)/2. The interaction is a contrast that tests whether the mean
difference for one factor depends on the level of the other factor, which is (A1B2 +
A2B1)/2 vs. (A1B1 + A2B2)/2.
Some sample plots follow. For the first plot, there is a B main effect, but
no A main effect and no interaction, as the effect of B does not depend on the level
of A. For the second plot, notice how the mean difference for B is the same at each
level of A and the difference in A is the same for each level of B, hence there is no
statistical interaction. The final plot also has main effects for A and B, but here
also has an interaction: we see the effect of B depends on the level of A (0 for A1
but 2 for A2), i.e., the effect of the diet depends on the genotype. We also see here
the interpretation of the main effects depends on whether there is an interaction or
not.
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p- values
For statistical significance testing, p-values are given. The lower the p-value,
the more evidence we have that the null hypothesis (typically that two population
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means are equal) is not true. If “statistical significance” is declared for p-values
less than 0.05, then 5% of the time we incorrectly conclude the means are different,
when actually they are the same.
The p-value is the probability that the test statistic is at least as extreme as
observed in this experiment given that the null hypothesis is true. Hence, the more
extreme the statistic, the lower the p-value and the more evidence the data gives
against the null hypothesis.
q-values
The level of 0.05 is the false positive rate when there is one test. However, for
a large number of tests we need to account for false positives. There are different
methods to correct for multiple testing. The oldest methods are family-wise error
rate adjustments (Bonferroni, Tukey, etc.), but these tend to be extremely
conservative for a very large number of tests. With gene arrays, using the False
Discovery Rate (FDR) is more common. The family-wise error rate adjustments
give one a high degree of confidence that there are zero false discoveries. However,
with FDR methods, one can allow for a small number of false discoveries. The
FDR for a given set of compounds can be estimated using the q-value (see Storey
J and Tibshirani R. (2003) Statistical significance for genomewide studies. Proc.
Natl. Acad. Sci. USA 100: 9440-9445; PMID: 12883005).
In order to interpret the q-value, the data must first be sorted by the p-value then
choose the cutoff for significance (typically p<0.05). The q-value gives the false
discovery rate for the selected list (i.e., an estimate of the proportion of false
discoveries for the list of compounds whose p-value is below the cutoff for
significance). For Table 1 below, if the whole list is declared significant, then the
false discovery rate is approximately 10%. If everything from Compound 079 and
above is declared significant, then the false discovery rate is approximately 2.5%.
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Table 10: Example of q-value interpretation
p -value

Compound

Compound 103
Compound 212
Compound 076
Compound 002
Compound 168
Compound 079
Compound 113
Compound 050
Compound 098
Compound 267

0.0002
0.0004
0.0004
0.0005
0.0006
0.0016
0.0052
0.0053
0.0061
0.0098

q -value
0.0122
0.0122
0.0122
0.0122
0.0122
0.0258
0.0631
0.0631
0.0647
0.0939

Principal Components Analysis (PCA)
Principal components analysis is an unsupervised analysis that reduces the
dimension of the data. Each principal component is a linear combination of every
metabolite and the principal components are uncorrelated. The number of principal
components is equal to the number of observations.
The first principal component is computed by determining the coefficients of
the metabolites that maximizes the variance of the linear combination. The second
component finds the coefficients that maximize the variance with the condition that
the second component is orthogonal to the first. The third component is orthogonal
to the first two components and so on. The total variance is defined as the sum of
the variances of the predicted values of each component (the variance is the square
of the standard deviation), and for each component, the proportion of the total
variance is computed. For example, if the standard deviation of the predicted values
of the first principal component is 0.4 and the total variance = 1, then 100*0.4*0.4/1
= 16% of the total variance is explained by the first component. Since this is an
unsupervised method, the main components may be unrelated to the treatment
groups, and the “separation” does not give an estimate of the true predictive ability.
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